{"id":"NCT02087059","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis","officialTitle":"A Multicenter, Open-label Clinical Study of the JAK Inhibitor Ruxolitinib (INC424) in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04","primaryCompletion":"2015-03","completion":"2015-04","firstPosted":"2014-03-14","resultsPosted":"2016-07-11","lastUpdate":"2016-07-11"},"enrollment":51,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Myelofibrosis (MF)"],"interventions":[{"type":"DRUG","name":"Ruxolitinib","otherNames":[]}],"arms":[{"label":"Ruxolitinib","type":"EXPERIMENTAL"}],"summary":"This is an open-label, multicenter clinical study in order to collect and examine data concerning the safety and efficacy of ruxolitinib in patients with Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Post-Essential Thrombocythemia (ET) MF.","primaryOutcome":{"measure":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability","timeFrame":"24 weeks","effectByArm":[{"arm":"Ruxolitinib","deltaMin":50,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":29,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":51},"commonTop":["Anaemia","Thrombocytopenia","Platelet count decreased","Constipation","Hepatic function abnormal"]}}